The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: A randomised, double-blind, placebo-controlled study

European Urology

Volumn 47, Issue 3, 2005, Pages 340-345

  Nieminen, Tuomo ^a   Ylitalo, Ritva ^a   Kööbi, Tiit ^a,b   Ylitalo, Pauli ^a,b   Kähönen, Mika ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adrenergic receptor blocker; Haemodynamics; Head up tilt; 1 blocker

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; TAMSULOSIN;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INDEX; HEART RATE; HEART STROKE VOLUME; HUMAN; IMPEDANCE CARDIOGRAPHY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDING; STATISTICAL SIGNIFICANCE; SUPINE POSITION; SYSTEMIC VASCULAR RESISTANCE; TILT TABLE TEST; VASODILATATION;

EID: 13844281594     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.11.002     Document Type: Article

References (24)

1. 1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study Clin Ther 23 2001 727 743
2. A. Tewari, and P. Narayan Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy Urology 53 3 Suppl 3a 1999 14 20
3. B. Djavan, and M. Marberger A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1999 1 13
4. M.C. Michel, M.T. Flannery, and P. Narayan Worldwide experience with alfuzosin and tamsulosin Urology 58 2001 508 516
5. Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003;CD002081.
6. K.E. Andersson The concept of uroselectivity Eur Urol 33 Suppl 2 1998 7 11
7. F.M. Debruyne Alpha blockers: are all created equal? Urology 56 5 Suppl 1 2000 20 22
8. S. Guimaraes, and D. Moura Vascular adrenoceptors: an update Pharmacol Rev 53 2001 319 356
9. C.G. Roehrborn Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker Urology 58 6 Suppl 1 2001 55 63
10. 1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia J Urol 171 2004 1029 1035
11. S.Z. Langer History and nomenclature of alpha1-adrenoceptors Eur Urol 36 Suppl 1 1999 2 6
12. M.C. Michel, B. Grubbel, K. Taguchi, F. Verfurth, T. Otto, and D. Kropfl Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha1-adrenoceptor subtypes and in human prostate J Auton Pharmacol 16 1996 21 28
13. R.F. Schafers, B. Fokuhl, A. Wasmuth, H. Schumacher, K. Taguchi, and C. de Mey Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin Br J Clin Pharmacol 47 1999 67 74
14. H. Matsushima, H. Kamimura, Y. Soeishi, T. Watanabe, S. Higuchi, and M. Tsunoo Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans Drug Metab Dispos 26 1998 240 245
15. T. Koobi, S. Kaukinen, T. Ahola, and V.M. Turjanmaa Non-invasive measurement of cardiac output: whole-body impedance cardiography in simultaneous comparison with thermodilution and direct oxygen Fick methods Intensive Care Med 23 1997 1132 1137
16. T. Koobi, S. Kaukinen, V.M. Turjanmaa, and A.J. Uusitalo Whole-body impedance cardiography in the measurement of cardiac output Crit Care Med 25 1997 779 785
17. M.I. Tishchenko Measurement of the stroke volume by integral rheogram of the human body Sechenov Physiol J 59 1973 1216 1224
18. T. Koobi, M. Kahonen, T. Iivainen, and V. Turjanmaa Simultaneous non-invasive assessment of arterial stiffness and haemodynamics - a validation study Clin Physiol Funct Imaging 23 2003 31 36
19. C.R. Chapple, J.J. Wyndaele, J. Nordling, F. Boeminghaus, A.F. Ypma, and P. Abrams Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group Eur Urol 29 1996 155 167
20. C. de Mey Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being Eur Urol 34 Suppl 2 1998 18 28
21. H. Lepor, S.A. Kaplan, I. Klimberg, D.F. Mobley, A. Fawzy, and M. Gaffney Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group J Urol 157 1997 525 530
22. T.F. Mets Drug-induced orthostatic hypotension in older patients Drugs Aging 6 1995 219 228
23. O.E. Brodde, and M.C. Michel Adrenergic and muscarinic receptors in the human heart Pharmacol Rev 51 1999 651 690
24. T. Nieminen, T. Koobi, and V. Turjanmaa Can stroke volume and cardiac output be determined reliably in a tilt-table test using the pulse contour method? Clin Physiol 20 2000 488 495